To combat rising costs, BCBSM installed a multi-year cost-cutting initiative to slice $600 million off its total spend, which has resulted in hundreds of job losses at the insurer. A total of 1,300 ...

BCBS Michigan saved $67 million and $80 million in 2024 and 2025, respectively, through biosimilar use, the insurer reported Feb. 17. The company began moving members from Humira and Stelara to ...

Johnson & Johnson has reported new long‑term results from the QUASAR long‑term extension study, showing that Tremfya (guselkumab) sustained clinical, endoscopic and histologic outcomes through week ...

The use of biosimilars saved Blue Cross members and employee groups $67 million in 2024 and $80 million in 2025, according to a news release. The savings come amid a cost-cutting push at Blue Cross to ...

When prescription prices keep climbing, patients are forced into impossible decisions — skipping doses, delaying treatment or choosing between medication and other basic needs. For people with Crohn’s ...

Johnson & Johnson JNJ has one of the most diverse revenue streams in the industry within its pharmaceuticals division, called Innovative Medicine. The company has several multi-million-dollar drugs ...

It’s rare that terms such as “life changing,” “tremendous advance,” or “a difference of night and day” describe an evolving class of therapeutics without sounding like hyperbole. But in the case of ...

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term ...

SEATTLE--(BUSINESS WIRE)--The Seattle facility of AGC Biologics, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from Agência Nacional de Vigilância Sanitária ...

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension ...